Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-367-750"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-367-750"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-368-0002
lpv:speaker	lp:Anne Delvaux2
lpv:spokenAs	member; EPP (2009-07-14--2014-06-30)3 substitute; AFET (2012-01-19--2014-06-30)3 member; ENVI (2012-01-19--2014-06-30)3 substitute; FEMM (2012-01-19--2014-06-30)3 substitute; Delegation for relations with South Africa (2009-09-16--2014-06-30)3 member; Delegation to the ACP-EU Joint Parliamentary Assembly (2009-09-16--2014-06-30)3 unknown; Centre Démocrate Humaniste (2009-07-14--2014-06-30)3 member; Delegation for relations with the Pan-African Parliament (2009-09-16--2014-06-30)3
lpv:translated text	"We have ratified by a large majority the amendments made to the European legislation on pharmacovigilance. The aim of these amendments is to compensate for the shortcomings of the new regulation and new directive (that came into force in July 2012), following the sadly famous Mediator scandal. The amendments made to the European texts, which are of the utmost importance as regards public health, will reinforce the European system for detecting and assessing potential problems with medicines in all of the EU Member States. The new rules, which result from an ordinary legislative procedure with the Council of Ministers, will come into force in 2013."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph